Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34‐selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative option for primary hemophagocytic lymphohistiocytosis (HLH), a rare disease of infants and young children, characterized by recurrent fever, hepatosplenomegaly, and cytopenia. We report a case of successful engraftment and stable full‐donor chimerism in a patient with HLH who underwent peripheral allogeneic CD34‐selected HSCT. The donor was his 1‐antigen‐HLA‐mismatched grandmother. After a conditioning regimen based on the combination of thiotepa, fludarabine, melphalan, and rabbit antilymphocyte serum, the patient received a megadose of 26.3 × 106/kg of CD34+ peripheral blood cells. Neutrophil (>0.5 × 109/L) and platelet (>50 × 109/L) engraftment was observed on days +16 and +12, respectively, and the patient was discharged home on day +24. No acute or chronic GVHD was observed. Infectious complications were the main causes of re‐hospitalization in the first year after transplantation, but no significant morbidity was observed thereafter. Thirty‐two months after HSCT, the patient is alive and well, still in complete clinical remission of his underlying disease with a durable engraftment, normal NK activity and full donor chimerism. This case suggests that a fludarabine‐based conditioning regimen and CD34‐selected peripheral allogeneic HSCT may be a feasible option in case of unavailability of a fully HLA‐matched related or unrelated donor. Am. J. Hematol. 72:143–146, 2003. © 2003 Wiley‐Liss, Inc.

[1]  C. Craddock,et al.  Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. , 2002, Blood.

[2]  F. Frassoni,et al.  Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM) , 2001, Bone Marrow Transplantation.

[3]  P. Thall,et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.

[4]  M. Dürken,et al.  Bone Marrow Transplantation in Hemophagocytic Lymphohistiocytosis , 2001, Leukemia & lymphoma.

[5]  A. Fischer,et al.  Perforin gene defects in familial hemophagocytic lymphohistiocytosis. , 1999, Science.

[6]  N. Kröger,et al.  Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single‐centre experience of 12 patients , 1999, British journal of haematology.

[7]  A. Fischer,et al.  Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity. , 1999, American journal of human genetics.

[8]  P. Sham,et al.  Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. , 1999, American journal of human genetics.

[9]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[10]  M. Steinbuch,et al.  Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. , 1997, Blood.

[11]  R. Egeler,et al.  HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. , 1997, Medical and pediatric oncology.

[12]  A. Fischer,et al.  Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. , 1996, Leukemia.

[13]  J. Klein,et al.  Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. , 1996, Bone marrow transplantation.

[14]  S. Bearman,et al.  The syndrome of hepatic veno-occlusive disease after marrow transplantation. , 1995, Blood.

[15]  G. Vassal,et al.  Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. , 1992, Bone marrow transplantation.

[16]  F. Appelbaum,et al.  Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.